Which Class I subclass is most associated with QT interval prolongation due to added potassium channel blockade?
Choose an answer, then check it.
Clinical Pharmacology · Antiarrhythmic Medications
Sodium Channel Blockers
On this page 6 sections
In 30 seconds
Class I antiarrhythmics block the fast sodium channels that drive the upstroke of the cardiac action potential, slowing conduction through heart tissue. They split into three subclasses — IA, IB, and IC — based on how strongly they bind sodium channels and what else they do to the action potential. Each has a signature use and a signature danger: IA risks QT prolongation and unique toxicities, IB causes CNS side effects, and IC can be lethal in a damaged heart despite working well in a healthy one. The unifying warning is that every antiarrhythmic can itself provoke new, sometimes worse, arrhythmias.
The college version
The Action Potential and the Vaughan Williams Framework
A normal heartbeat depends on an orderly electrical sequence inside each cardiac cell. Fast-opening sodium channels create the sharp upstroke (phase 0) that lets the impulse race from cell to cell; potassium channels then repolarize the cell so it can fire again. The Vaughan Williams classification sorts antiarrhythmics by which part of this cycle they target: Class I blocks sodium channels, Class II blocks beta-adrenergic receptors, Class III blocks potassium channels, and Class IV blocks calcium channels. Class I drugs slow the sodium-dependent upstroke, which slows conduction velocity through atrial muscle, ventricular muscle, and the His-Purkinje system. Because sodium channels cycle between resting, open, and inactivated states, how a drug binds and releases from the channel determines its subclass and its clinical personality.
Class IA: Quinidine, Procainamide, Disopyramide
Class IA agents produce intermediate sodium channel blockade and, unlike IB or IC, also block potassium channels. That dual action slows conduction while prolonging the action potential and the QT interval, so ECG monitoring for QT changes is essential. Quinidine carries a distinctive toxicity called cinchonism — tinnitus, headache, visual disturbance, and confusion. Procainamide carries two separate risks: long-term use can trigger drug-induced lupus (joint pain, rash, positive antinuclear antibodies), and it can cause agranulocytosis, so blood counts warrant attention. Disopyramide adds prominent anticholinergic effects like dry mouth, urinary retention, and constipation. All three can worsen heart failure through negative inotropy, and their QT-prolonging effect creates risk for torsades de pointes, so electrolyte status — particularly potassium and magnesium — needs monitoring alongside the ECG.
Class IB: Lidocaine and Mexiletine
Class IB drugs bind sodium channels weakly and dissociate quickly, but show a striking preference for tissue that is ischemic, depolarized, or otherwise abnormal — exactly the kind of tissue generating dangerous ventricular arrhythmias after a heart attack. In healthy, normally polarized tissue their effect is minimal, which is why they are comparatively safer for the normal heart. Rather than prolonging the action potential like IA drugs, Class IB agents shorten it. Lidocaine treats acute ventricular arrhythmias, while mexiletine is its oral counterpart for longer-term management. Their defining toxicity is neurologic rather than cardiac: perioral numbness or tingling, confusion, tremor, and, at higher exposure, seizures — reflecting sodium channel blockade in the central nervous system.
Class IC: Flecainide and Propafenone
Class IC agents bind sodium channels most strongly and dissociate slowest, producing the most pronounced conduction slowing and QRS widening on ECG. They are highly effective at suppressing atrial fibrillation in patients whose hearts are structurally normal, and flecainide is used in the "pill-in-the-pocket" strategy, where a patient takes a dose only when an episode begins, rather than daily. The key teaching point: Class IC drugs are contraindicated in structural heart disease and prior myocardial infarction, since in scarred myocardium their potent conduction slowing becomes strongly proarrhythmic and raises mortality risk. Because they slow the AV node less than they slow atrial tissue, they can paradoxically let atrial flutter conduct to the ventricles one-to-one, producing a dangerously fast rate; they are typically paired with an AV nodal blocking agent.
The Overarching Principle
Every antiarrhythmic drug, by altering the heart's electrical properties, can also create the substrate for new arrhythmias — a phenomenon called proarrhythmia. Routine surveillance with ECG tracings and serum electrolytes is therefore not optional monitoring but a core part of safe use for the entire class.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Imagine each heart cell has tiny doors that snap open to let a signal zoom through, like a relay race baton getting passed super fast. Class I medicines are like door-stoppers that make the doors open a little slower, so the signal moves through the heart more sluggishly. Some door-stoppers (IA) also mess with a different set of doors and can make the "reset" step take longer. Some (IB) are weak and mostly only jam doors in parts of the heart that are already hurt, and they can make your lips feel tingly if there's too much around. Some (IC) are the strongest — great at calming a healthy heart's irregular rhythm, but if the heart already has scars or damage, jamming the doors that hard can backfire badly and become dangerous. That's why doctors always keep an eye on the heart's electrical picture and the body's mineral levels whenever these medicines are used.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient receiving lidocaine for a ventricular arrhythmia reports numbness around the mouth and mild confusion. What is happening, and what class does this reflect?
Show answer
Perioral numbness and confusion during lidocaine therapy reflect central nervous system sodium channel blockade, a hallmark toxicity of Class IB agents.
Lidocaine blocks sodium channels throughout the body, not just the heart, so too much of it affects nerve cells in the brain and around the mouth, causing tingling and confusion, and seizures if it builds up further.
Explain why a physician prescribing flecainide for atrial flutter would also add an AV nodal blocking drug.
Show answer
Flecainide slows conduction more in the atria than at the AV node, so without also slowing the AV node, a fast atrial flutter signal could pass through to the ventricles one-to-one, creating a dangerously rapid heart rate.
Adding an AV nodal blocker prevents that 1:1 conduction so the ventricles keep beating at a safer, slower pace.
Quick check
3 questions here. Answers stay hidden until you check.
A patient on long-term procainamide develops joint pain and a positive antinuclear antibody test. This is most consistent with which known effect?
Choose an answer, then check it.
Why are Class IC agents like flecainide contraindicated in patients with structural heart disease or prior myocardial infarction?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.